Want to see EDVA full AI Analyst Report?
Top Page
Endovia Health Sciences Inc
(NYSE MKT:EDVA)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.16
▼(-62.38% Downside)
Action:Reiterated
Date:10/06/26
The score is driven primarily by very weak financial performance (collapsed revenue, large ongoing losses, negative equity, and continued cash burn). Technicals also remain bearish with the stock below major moving averages and negative MACD, despite oversold readings. Corporate events provide some offset via FDA-related progress, but funding actions highlight dilution/refinancing risk.
Positive Factors
FDA veterinary pathway
MUMS status gives CannEpil a defined conditional-approval route and advances the program beyond basic concept stage. If the planned FDA discussions, studies, manufacturing work, and filings succeed, the company could establish a regulated veterinary product in an unmet-need market.
Negative Factors
Severe revenue deterioration
The sharp revenue contraction indicates that the existing commercial base is not currently providing a dependable operating platform. Extremely low or abnormal reported sales also make the business far from breakeven and increase dependence on successful future product development.
Read all positive and negative factors
Positive Factors
Negative Factors
FDA veterinary pathway
MUMS status gives CannEpil a defined conditional-approval route and advances the program beyond basic concept stage. If the planned FDA discussions, studies, manufacturing work, and filings succeed, the company could establish a regulated veterinary product in an unmet-need market.
Read all positive factors
Endovia Health Sciences Inc (EDVA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.06M
Dividend YieldN/A
Average Volume (3M)4.90M
Price to Earnings (P/E)―
Beta (1Y)1.75
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees2
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-26.79
Shares Outstanding6,412,521
10 Day Avg. Volume13,871,410
30 Day Avg. Volume4,901,220
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.10
Price to Sales (P/S)20.57
P/FCF Ratio-0.31
Enterprise Value/Market Cap7.56
Enterprise Value/Revenue-22.29
Enterprise Value/Gross Profit-12.71
Enterprise Value/Ebitda-0.59
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-52.8
Revenue Forecast (FY)$17.89M
Endovia Health Sciences Inc Business Overview & Revenue Model
Company Description
Endovia Health Sciences is a diversified cannabinoid-based health sciences platform. The company's strategy focuses on three main areas: commercializing differentiated cannabinoid-based pharmaceutical products internationally, advancing cannabinoi...
How the Company Makes Money
Splash Beverage Group primarily makes money by selling packaged beverage products under its brand portfolio into wholesale and retail channels. Revenue is generally generated when products are shipped/sold to distributors, retailers, or other chan...
Endovia Health Sciences Inc Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
8
Very Negative
Cash Flow
7
Very Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Endovia Health Sciences Inc Technical Analysis
Negative
0.42
Price Trends
0.30
Negative
0.50
Negative
1.32
Negative
Market Momentum
-0.04
Negative
30.58
Neutral
16.46
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EDVA, the sentiment is Negative. The current price of 0.42 is above the 20-day moving average (MA) of 0.21, above the 50-day MA of 0.30, and below the 200-day MA of 1.32, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 30.58 is Neutral, neither overbought nor oversold. The STOCH value of 16.46 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EDVA.
Endovia Health Sciences Inc Risk Analysis
Endovia Health Sciences Inc disclosed 42 risk factors in its most recent earnings report. Endovia Health Sciences Inc reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Endovia Health Sciences Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $2.05B | 19.28 | 6.96% | 2.57% | 0.56% | -28.00% | |
57 Neutral | $6.87B | -3.20 | -22.65% | 5.17% | -1.77% | -326.16% | |
55 Neutral | $1.73B | -25.09 | -8.89% | ― | -6.06% | -195.51% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | $1.06M | -0.02 | 170.79% | ― | ― | ― |
* Healthcare Sector Average
EDVA
Endovia Health Sciences Inc
0.17
-8.87
-98.15%
SAM
Boston Beer
170.37
-49.77
-22.61%
CCU
Compania Cervecerias Unidas SA
11.09
-0.56
-4.84%
TAP
Molson Coors
36.91
-6.72
-15.41%
YHC
LQR House
1.27
-80.73
-98.45%
IBG
Innovation Beverage Group Ltd.
0.89
-16.11
-94.76%
Endovia Health Sciences Inc Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Endovia Health Raises Capital Through Recent Equity Issuance
Positive
Oct 6, 2026
On September 30, 2026, Endovia Health Sciences, Inc. issued 526,582 shares of common stock to C/M Capital Master Fund, LP under a previously disclosed securities purchase agreement dated September 19, 2025, raising gross proceeds of $81,830.84. Th...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Endovia Gains MUMS Status for CannEpil Canine Therapy
Positive
Oct 5, 2026
On October 5, 2026, Endovia Health Sciences, in partnership with Lupvindol BioSciences, reported that the FDA’s Center for Veterinary Medicine has determined CannEpil, a proprietary oral CBD and THC solution for pain associated with bone can...
Business Operations and StrategyPrivate Placements and Financing
Endovia Secures New Funding to Advance CannEpil Program
Neutral
Sep 24, 2026
On September 18, 2026, Endovia Health Sciences entered into a letter agreement with C/M Capital Master Fund, LP, under which the investor committed to provide at least $1 million to support development and commercialization of CannEpil®. The ...
Business Operations and StrategyPrivate Placements and Financing
Endovia secures $500,000 convertible financing for CannEpil
Positive
Sep 22, 2026
Endovia Health Sciences, Inc., a NYSE American‑listed cannabinoid health sciences company, has closed an initial $500,000 tranche of secured convertible debt financing from C/M Capital Master Fund, LP as of September 22, 2026. This represent...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related AnnouncementsRegulatory Filings and Compliance
Endovia advances CannEpil amid supportive federal rescheduling move
Positive
Aug 31, 2026
On August 31, 2026, Endovia Health Sciences, Inc. welcomed the federal government’s support during recent DEA administrative hearings for moving marijuana from Schedule I to Schedule III, calling it a historic shift toward a clearer regulato...
Private Placements and FinancingRegulatory Filings and Compliance
Endovia Health Sciences Raises Capital Through Equity Offering
Positive
Aug 28, 2026
On August 25, 2026, Endovia Health Sciences, Inc. raised $107,610.62 in gross proceeds through the sale and issuance of 510,951 shares of common stock to C/M Capital Master Fund, LP under a previously disclosed Securities Purchase Agreement dated ...
Business Operations and StrategyExecutive/Board Changes
Endovia appoints interim leaders with incentive-focused pay
Positive
Aug 26, 2026
On August 20, 2026, Endovia Health Sciences, Inc. appointed Brady Cobb as interim chief executive officer and Michael Bondurant as interim chief operating officer under new employment agreements that set base salaries of $300,000 and $275,000, res...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Endovia launches FDA-backed CannEpil veterinary pain program
Positive
Aug 25, 2026
On August 25, 2026, Endovia Health Sciences announced that the U.S. Food and Drug Administration’s Center for Veterinary Medicine has opened Investigational New Animal Drug File No. 14145 for the company’s CannEpil® veterinary pro...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.